Peter Høngaard Andersen

Dr. Høngaard Andersen has over 25 years of experience in drug discovery and development. He is currently Chairman of the Board of Directors of Scandion Oncology A/S and of the Innovation Board in the Association of Danish Regions and member of the board of Immunovia AB. Dr. Høngaard Andersen spent 14 years at Novo Nordisk(CNS, neuroendocrinology, women health, type 2 diabetes) and 15 years at Lundbeck CNS(drug discovery and early development). He has been involved in the discovery and development of several drugs on the market (e.g., Norditropine Simplexx®, Victoza®, Trintellix/Brintellix®, Cipralex®), has founded or co-founded several biotech companies e.g. Acadia Pharmaceuticals, Zealand Pharma, Glycom, Serendex, Epitherapeutics, Prexton Pharmaceuticals.

Previously he was involved in Innovative Medicines Initiative (IMI) from the beginning in 2003, was chairing the industry side of IMI from 2009 – 2014 and founded Innovation Fund Denmark in 2014 where he served as Managing Director until May 2019.

Dr. Høngaard Andersen received his Bachelor’s degree in Chemistry (1980), M. Sc. in Biochemistry (1983) and is Dr. Med. (1994).